{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:18:20Z","timestamp":1792293500464,"version":"4.4.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1001\/jamadermatol.2018.1912","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T03:51:32Z","timestamp":1531972292000},"page":"1057","source":"Crossref","is-referenced-by-count":112,"title":["Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy"],"prefix":"10.1001","volume":"154","author":[{"given":"Leo L.","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Patel","sequence":"additional","affiliation":[{"name":"Aesthetic Dermatology, Media, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelma C.","family":"Chiesa-Fuxench","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"McGettigan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Schuchter","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara C.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Ming","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"dbr180010r1","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports.","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"dbr180010r2","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"dbr180010r3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review.","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"dbr180010r4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti\u2013PD-1\/PD-L1 immune checkpoint antibodies.","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"dbr180010r5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cup.13059","article-title":"Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti\u2013PD-1 therapy.","volume":"45","author":"Shao","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"2","key":"dbr180010r6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cup.2017.44.issue-2","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"7","key":"dbr180010r7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma.","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"dbr180010r8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"issue":"9","key":"dbr180010r9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/cup.2016.43.issue-9","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.","volume":"43","author":"Mochel","year":"2016","journal-title":"J Cutan Pathol"},{"issue":"34","key":"dbr180010r10","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials.","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"dbr180010r11","first-page":"JCO2017756270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","author":"Robert","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"dbr180010r12","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.3747\/co.20.1265","article-title":"Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases.","volume":"20","author":"Assi","year":"2013","journal-title":"Curr Oncol"},{"issue":"5","key":"dbr180010r13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","article-title":"Histopathologic features of colitis due to immunotherapy with anti\u2013PD-1 antibodies.","volume":"41","author":"Chen","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"dbr180010r14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab.","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"dbr180010r15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A molecular and preclinical comparison of the PD-1\u2013targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.","volume":"44","author":"Fessas","year":"2017","journal-title":"Semin Oncol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2687546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T11:31:21Z","timestamp":1536751881000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.1912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.1912","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}